紫杉醇联合不同铂类药物化疗在晚期卵巢癌中的疗效和安全性研究

Effect and safety of paclitaxel combined with different platinum chemotherapy in treating advanced ovarian cancer

目的:研究紫杉醇联合不同铂类药物化疗在晚期卵巢癌中的疗效和安全性。方法:将90例晚期卵巢癌患者纳入研究,采用随机数表法分为观察组和对照组,观察组给予紫杉醇135 mg/m2、奈达铂80 mg/m2静脉滴注;对照组给予紫杉醇135 mg/m2、顺铂20 mg/m2静脉滴注。观察患者化疗效果、不良反应以及远期存活情况。结果:①观察组患者的TNM分期、VEGFA和VEGFB含量均低于对照组;②观察组患者发生厌食、恶心呕吐、白细胞减少、血小板减少、血肌酐升高、ALT升高及肺毒性的例数均少于对照组;③术后1年、2年和3年时观察组患者的存活率高于对照组。结论:紫杉醇联合奈达铂能够取得显著的化疗效果,并可减少不良反应,延长存活时间,是极为高效、低毒的化疗方案。

Objective： To study the effect and safety of paclitaxel combined with different platinum chemotherapy in treating advanced ovarian cancer. Methods： advanced ovarian cancer patients in our hospital from June 2008 to June 2009 were enrolled and divided into observation group according to random number table. Observation group given 135 mg/m2 paclitaxel and 80 mg/m2 nedaplatin; control group given 135 mg/m2 paclitaxel and 20 mg/m2 cisplatin. Then chemotherapy effect, toxicity and long-term survival condition were observed. Results：（1）TNM stage and VEGFA, VEGFB content of observation group were lower than those of control group;（2）cases of anorexia, nausea and vomiting, leukopenia, thrombocytopenia, increasing serum creatinine, elevated ALT, pulmonary toxicity were lower than those of control group;（3）1 years, 2 years, 3 years after chemotherapy, survival cases of observation group were more than those of control group. Conclusion： Paclitaxel combined with nedaplatin are more efficient and low toxic chemotherapy for it can achieve more exact effect and reduce side effects.